In recent years, the United Arab Emirates (UAE) has been at the forefront of advancements in healthcare technology, particularly in the 3D ultrasound market. This market is evolving from a high-end niche to a procedural standard, driven by increasing clinical demand for volumetric quantification in prenatal cardiology and image-guided interventions.
On April 12, 2026, Sheikh Khaled bin Mohamed bin Zayed Al Nahyan arrived in Beijing, China, to further strengthen ties and explore collaborative opportunities in healthcare technology. This visit underscores the UAE’s commitment to becoming a regional reference and training hub for advanced ultrasound applications.
One significant development in this landscape is the introduction of the UAE’s R&D tax credit regime, established under Cabinet Decision No. 215 of 2025. This initiative aims to incentivize research and development in the healthcare sector, offering a headline rate of 50% on qualifying expenditure.
The R&D tax credit operates on a tiered structure, with three tiers: 15% for qualifying expenditures of 1 million AED, 35% for 2 million AED, and 50% for 5 million AED. This structure is designed to encourage companies to invest in innovative technologies and processes.
Moreover, Ministerial Decision No. 24 of 2026 has operationalized this tax credit, making it a vital tool for companies looking to enhance their R&D capabilities. The dual-threshold design of the credit has direct transfer pricing implications, as compliance is a condition precedent to credit qualification.
As the installed base refresh cycle accelerates due to software-driven obsolescence, the UAE’s healthcare sector is poised for rapid growth. The transition to 3D ultrasound as a procedural standard is not only a technological advancement but also a response to the increasing demands of healthcare professionals and patients alike.
Currently, the UAE serves as a regional reference and training hub for advanced ultrasound applications, attracting attention from neighboring countries looking to enhance their own healthcare systems. This positioning is critical for the UAE as it seeks to establish itself as a leader in medical innovation.
The implications of these developments are significant for stakeholders involved, including healthcare providers, technology companies, and patients. The enhanced R&D environment and the transition to standardized procedures will likely improve patient outcomes and operational efficiencies across the healthcare spectrum.
As the UAE continues to invest in healthcare technology and innovation, it sets a precedent for other nations in the region. The focus on R&D and procedural standardization in ultrasound technology is a clear indication of the UAE’s strategic vision for the future of healthcare.
